Córdoba‐Jover et al., 2023 - Google Patents
Tcf20 deficiency is associated with increased liver fibrogenesis and alterations in mitochondrial metabolism in mice and humansCórdoba‐Jover et al., 2023
View PDF- Document ID
- 5947492721782120393
- Author
- Córdoba‐Jover B
- Ribera J
- Portolés I
- Lecue E
- Rodriguez‐Vita J
- Pérez‐Sisqués L
- Mannara F
- Solsona‐Vilarrasa E
- García‐Ruiz C
- Fernández‐Checa J
- Casals G
- Rodríguez‐Revenga L
- Álvarez‐Mora M
- Arteche‐López A
- Díaz de Bustamante A
- Calvo R
- Pujol A
- Azkargorta M
- Elortza F
- Malagelada C
- Pinyol R
- Huguet‐Pradell J
- Melgar‐Lesmes P
- Jiménez W
- Morales‐Ruiz M
- Publication year
- Publication venue
- Liver International
External Links
Snippet
Abstract Background & Aims Transcription co‐activator factor 20 (TCF20) is a regulator of transcription factors involved in extracellular matrix remodelling. In addition, TCF20 genomic variants in humans have been associated with impaired intellectual disability. Therefore, we …
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Hybridisation probes
- C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Xia et al. | Reciprocal control of obesity and anxiety–depressive disorder via a GABA and serotonin neural circuit | |
| Dobson-Stone et al. | CYLD is a causative gene for frontotemporal dementia–amyotrophic lateral sclerosis | |
| Kurz et al. | A53T-alpha-synuclein overexpression impairs dopamine signaling and striatal synaptic plasticity in old mice | |
| Cappello et al. | Mutations in genes encoding the cadherin receptor-ligand pair DCHS1 and FAT4 disrupt cerebral cortical development | |
| Panitch et al. | Integrative brain transcriptome analysis links complement component 4 and HSPA2 to the APOE ε2 protective effect in Alzheimer disease | |
| Aoto et al. | ATP6V0A1 encoding the a1-subunit of the V0 domain of vacuolar H+-ATPases is essential for brain development in humans and mice | |
| Kishi et al. | Reduction of aberrant NF-κB signalling ameliorates Rett syndrome phenotypes in Mecp2-null mice | |
| Ahmad et al. | The zinc finger protein ZPR1 is a potential modifier of spinal muscular atrophy | |
| Kelley et al. | The cyclic AMP cascade is altered in the fragile X nervous system | |
| Mei et al. | Inhibiting MARSs reduces hyperhomocysteinemia‐associated neural tube and congenital heart defects | |
| US11788112B2 (en) | L-2-hydroxyglutarate and stress induced metabolism | |
| Yook et al. | A TBR1-K228E mutation induces Tbr1 upregulation, altered cortical distribution of interneurons, increased inhibitory synaptic transmission, and autistic-like behavioral deficits in mice | |
| Wang et al. | A positive feedback inhibition of isocitrate dehydrogenase 3β on paired-box gene 6 promotes Alzheimer-like pathology | |
| Yamada et al. | Increased stathmin1 expression in the dentate gyrus of mice causes abnormal axonal arborizations | |
| Iacomino et al. | Loss of Wwox perturbs neuronal migration and impairs early cortical development | |
| Li et al. | Aberrant palmitoylation caused by a ZDHHC21 mutation contributes to pathophysiology of Alzheimer’s disease | |
| Eid et al. | Single‐cell RNA‐seq uncovers novel metabolic functions of Schwann cells beyond myelination | |
| Córdoba‐Jover et al. | Tcf20 deficiency is associated with increased liver fibrogenesis and alterations in mitochondrial metabolism in mice and humans | |
| Hoeffer et al. | Regulator of calcineurin 1 modulates expression of innate anxiety and anxiogenic responses to selective serotonin reuptake inhibitor treatment | |
| Zhang et al. | Suppressing UBE2N ameliorates Alzheimer's disease pathology through the clearance of amyloid beta | |
| Tayran et al. | ABCA7-dependent induction of neuropeptide Y is required for synaptic resilience in Alzheimer’s disease through BDNF/NGFR signaling | |
| Auger et al. | unc5c haploinsufficient phenotype: striking similarities with the dcc haploinsufficiency model | |
| EP4426310A1 (en) | A method of treating depression by immune modulation | |
| Bai et al. | High homocysteine-thiolactone leads to reduced MENIN protein expression and an impaired DNA damage response: implications for neural tube defects | |
| Abbink et al. | Integrated stress response deregulation underlies vanishing white matter and is a target for therapy |